Atrial Fibrillation News and Research RSS Feed - Atrial Fibrillation News and Research

Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
New Johns Hopkins mobile app educates care providers on improving sleep, overall health of patients

New Johns Hopkins mobile app educates care providers on improving sleep, overall health of patients

Experts from the Johns Hopkins Center for Sleep hope to help patients get a better night’s sleep by providing health care staff members with a basic educational tool on their smartphones. [More]
Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

This week, three patients in the United States received the first implants of the Boston Scientific Corporation WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device. [More]
New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA. [More]
Catheter ablation more beneficial to heart failure patients than Amiodarone treatment

Catheter ablation more beneficial to heart failure patients than Amiodarone treatment

Among patients with heart failure and atrial fibrillation, those who underwent catheter ablation were less likely to die, be hospitalized or have recurrent atrial fibrillation than patients taking a heart rhythm regulating drug, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
Study: Remote ischemic preconditioning not effective in improving heart bypass outcomes

Study: Remote ischemic preconditioning not effective in improving heart bypass outcomes

Patients who underwent a simple conditioning procedure involving the inflation and deflation of a blood pressure cuff on the upper arm before coronary artery bypass grafting, known as heart bypass surgery, had no better long-term health outcomes than bypass patients who did not receive the conditioning, according to research presented at the American College of Cardiology's 64th Annual Scientific Session in San Diego. [More]
Study tracks long-term effects of weight loss on atrial fibrillation burden

Study tracks long-term effects of weight loss on atrial fibrillation burden

Obese patients with atrial fibrillation who lost at least 10 percent of their body weight were six times more likely to achieve long-term freedom from this common heart rhythm disorder compared to those who did not lose weight, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
Patients who receive ablation during mitral valve surgery have less episodes of atrial fibrillation

Patients who receive ablation during mitral valve surgery have less episodes of atrial fibrillation

Patients with atrial fibrillation who received ablation while they were already undergoing surgery to correct a leaky heart valve had fewer episodes of atrial fibrillation a year later compared to patients who had the valve surgery alone, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
Cardiome Pharma records net loss of $18.2 million for 2014

Cardiome Pharma records net loss of $18.2 million for 2014

Cardiome Pharma Corp. today reported financial results for its fourth quarter and year ended December 31, 2014. Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted accounting principles used in the United States of America (U.S. GAAP). [More]
Scientists develop mathematical model to digitally map communication between heart cells

Scientists develop mathematical model to digitally map communication between heart cells

A team of scientists led by Johns Hopkins cardiologist and biomedical engineer Hiroshi Ashikaga, M.D., Ph.D., has developed a mathematical model to measure and digitally map the beat-sustaining electrical flow between heart cells. [More]
AliveCor launches latest version of AliveECG app

AliveCor launches latest version of AliveECG app

AliveCor, Inc. announced today the launch of the latest version of the AliveECG app, with two new FDA-cleared and CE-marked automated detectors that allow patients and physicians to focus on the ECGs that matter most. [More]
New blood thinner reduces stroke risk in patients with atrial fibrillation

New blood thinner reduces stroke risk in patients with atrial fibrillation

Patients with high-risk atrial fibrillation, or AFib, often require one drug to regulate heart rhythm and a second drug to thin their blood and reduce the risk of stroke. [More]
ANI acquires approved ANDA for Flecainide Acetate tablets USP

ANI acquires approved ANDA for Flecainide Acetate tablets USP

ANI Pharmaceuticals, Inc. today announced that it has acquired the approved abbreviated new drug application ("ANDA") for Flecainide Acetate tablets USP 50mg, 100mg and 150mg, previously marketed by Teva Pharmaceuticals. [More]
New guidelines advise nearly all women, people with AFib to take blood thinners

New guidelines advise nearly all women, people with AFib to take blood thinners

Nearly all women and people over 65 in the U.S. with atrial fibrillation are advised to take blood thinners under new guidelines based on an analysis from the Duke Clinical Research Institute. [More]

Study demonstrates high compliance among patients using iRhythm's ECG patch monitors to detect AFib

iRhythm Technologies, Inc., a leading digital health care solutions company focusing on the advancement of cardiac care, presented study results that demonstrate high compliance among patients using long term electrocardiogram (ECG) patch monitors to detect atrial fibrillation (AFib). [More]
FDA clears AliveCor's automated detectors that record and display ECG rhythm

FDA clears AliveCor's automated detectors that record and display ECG rhythm

AliveCor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company clearance for two new algorithms giving users instant feedback on their electrocardiogram (ECG) recordings and expanding its automated interpretation service offerings. [More]
VATS lobectomy best for NSCLC patient short-term outcomes

VATS lobectomy best for NSCLC patient short-term outcomes

Video-assisted thoracoscopic surgery lobectomy offers better short-term outcomes for patients with early-stage non-small-cell lung cancer than open lobectomy, multi-institutional research confirms. [More]
AliveCor receives CE Mark clearance for algorithm to detect atrial fibrillation

AliveCor receives CE Mark clearance for algorithm to detect atrial fibrillation

AliveCor, Inc. announced today it has received CE Mark clearance for its automated analysis process (algorithm) to detect atrial fibrillation (AF), the most common heart rhythm disturbance and a leading cause of stroke. The latest version of the AliveECG app for users in the United Kingdom and Ireland now provides patients with real-time AF detection in electrocardiogram (ECG) recordings using the AliveCor Heart Monitor. [More]
Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration has approved SAVAYSA (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). [More]
New analysis finds global improvements in life expectancy

New analysis finds global improvements in life expectancy

Global life expectancy increased by 5.8 years in men and 6.6 years in women between 1990 and 2013, according to a major new analysis from the Global Burden of Disease Study 2013 (GBD 2013). [More]
Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco. [More]
Advertisement
Advertisement